ONCAlert | Upfront Therapy for mRCC

Head & Neck Cancers 1 MORE >>

Pembrolizumab has been approved by the FDA as monotherapy for newly diagnosed patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 and for use in combination with platinum and fluorouracil for this patient population, irrespective of PD-L1 expression.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.